{"url_path":"/sec/vtgn/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-046143-index.html","accession_number":"0001628280-26-046143","cik":"0001411685","ticker":"VTGN","issuer_name":"Vistagen Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-046143-index.html","primary_entity_key":"0001411685","primary_entity_name":"Vistagen Therapeutics, Inc."},"word_count":221,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure\n\nOn June 30, 2026, Vistagen Therapeutics, Inc. (the “Company”) issued a press release announcing topline and post-hoc data from the Company’s PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder. A copy of the press release is furnished as Exhibit 99.1 hereto.\n\nAs described in the press release, the Company will also host a conference call and webcast to discuss the topline and post-hoc data from its PALISADE-4 trial at 8:30 a.m. ET on June 30, 2026. A copy of the presentation to be used by the Company during the conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.\n\nThe information furnished pursuant to this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing."}